Key Takeaways

TANDEM aimed to characterize real-world prescribing behaviors and treatment outcomes of DTG/2DR in the US setting.

Here we aim to describe the outcomes of those initiated on DTG/3TC in the Test (T&T) setting.

After a median follow-up time of 1.3 years, 93.4% of the T&T subgroup achieved virological suppression, 3 (4.8%) did not, and 1 (1.6%) was still unknown.

Baseline Characteristics

Clinical characteristics are described in Table 2.

Virological Outcomes

Median (IQR) virological suppression was 9.8 (5.8, 17.7) in the T&T subgroup and 10.7 (5.4, 19.3) in the non-T&T subgroup.

The T&T subgroup was more likely to experience virological rebound, defined as a ≥200 copies/mL viremia following two consecutive viral load measurements of <200 copies/mL, after previously reaching <200 copies/mL.

Virologic rebound occurred in 6 TN PLWH overall, with 1 of these occurring in the T&T subgroup (0.48%; 95% CI: 0.06 to 3.00). The rebounding viremia in the T&T subgroup was of unknown etiology and was not classified as virological failure.

Table 3. Virological Outcomes

<table>
<thead>
<tr>
<th>Timing of Virologic Rebound Following DTG/3TC Initiation</th>
<th>Median (IQR)</th>
<th>Time to virological rebound following DTG/3TC initiation (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All PLWH (n=364)</td>
<td>3 (1, 7)</td>
<td>7 (10.5, 37.9)</td>
</tr>
<tr>
<td>All PLWH (n=62)</td>
<td>3 (1, 7)</td>
<td>7 (10.5, 37.9)</td>
</tr>
</tbody>
</table>

Table 2. Baseline Clinical Characteristics

Virologically suppressed, defined as virological suppression ≥12 weeks post initiation.

Virologically unsuppressed, defined as virological suppression <12 weeks post initiation.

Table 1. Baseline Demographics of DTG/3TC Sub-Cohorts

<table>
<thead>
<tr>
<th>Group</th>
<th>Median Age (years)</th>
<th>% Male</th>
<th>% White/Caucasian</th>
<th>% Hispanic/Latinx</th>
<th>% Black</th>
<th>% Asian</th>
<th>% Not Specified</th>
<th>Non-T&amp;T (n=51)</th>
<th>T&amp;T (n=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTG/3TC cohort</td>
<td>52 (49-55)</td>
<td>57.1%</td>
<td>39.2%</td>
<td>55.3%</td>
<td>11.3%</td>
<td>1.6%</td>
<td>2.4%</td>
<td>43.1%</td>
<td>58.5%</td>
</tr>
<tr>
<td>DTG/3TC T&amp;T</td>
<td>52 (49-55)</td>
<td>57.1%</td>
<td>39.2%</td>
<td>55.3%</td>
<td>11.3%</td>
<td>1.6%</td>
<td>2.4%</td>
<td>43.1%</td>
<td>58.5%</td>
</tr>
<tr>
<td>DTG/3TC Non-T&amp;T</td>
<td>52 (49-55)</td>
<td>57.1%</td>
<td>39.2%</td>
<td>55.3%</td>
<td>11.3%</td>
<td>1.6%</td>
<td>2.4%</td>
<td>43.1%</td>
<td>58.5%</td>
</tr>
</tbody>
</table>

Inclusion Criteria

• >18 years old;
• Had a diagnosis of HIV-1 infection;
• Had a history of antiretroviral therapy (ART) consisting of the 2DR DTG/3TC or DTG/2DR as a single regimen (T&T group); DTG/3TC cohort: were initiated on or after May 1, 2015 and before 30th September 2020.
• Upon initiation, PLWH must have been either initiation of ART (n=151) to ART-suppressed virologically suppressed on cART for ≥1 week with ≥100 copies/mL on cART, or a stable ART regimen for ≥12 months on a different DTG/2DR regimen.
• Have at least 6 months of clinical follow up from initiation of DTG/2DR treatment which could include time post discontinuation of either regimen.

Exclusion Criteria

• <18 years old;
• Did not have a diagnosis of HIV-1 infection;
• Had a history of antiretroviral therapy (ART) consisting of the 2DR DTG/3TC or DTG/2DR as a single regimen (T&T group); DTG/3TC cohort: were initiated on or after May 1, 2015 and before 30th September 2020.
• Upon initiation, PLWH must have been either initiation of ART (n=151) to ART-suppressed virologically suppressed on cART for ≥1 week with ≥100 copies/mL on cART, or a stable ART regimen for ≥12 months on a different DTG/2DR regimen.
• Have at least 6 months of clinical follow up from initiation of DTG/2DR treatment which could include time post discontinuation of either regimen.

Models

TANDEM was a US-based, retrospective chart review, 24 sites abstracted clinical data, and post-initiation outcomes data from medical charts of PLWH who were initiated on DTG/3TC or on DTG/3TC plus/minus NNRTI (DTG-RPV).

Data were descriptive and non-hypothetical in nature.

Virologically suppressed, defined as virological suppression ≥12 weeks post initiation.

Virologically unsuppressed, defined as virological suppression <12 weeks post initiation.

Virological rebound, defined as a ≥200 copies/mL viremia following two consecutive viral load measurements of <200 copies/mL, after previously reaching <200 copies/mL.

Non-T&T (n=62)

<table>
<thead>
<tr>
<th>Virological Outcomes</th>
<th>Median Age (years)</th>
<th>% Male</th>
<th>% White/Caucasian</th>
<th>% Hispanic/Latinx</th>
<th>% Black</th>
<th>% Asian</th>
<th>% Not Specified</th>
<th>Non-T&amp;T (n=51)</th>
<th>T&amp;T (n=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to virological suppression following DTG/3TC initiation (weeks)</td>
<td>3 (1, 7)</td>
<td>57.1%</td>
<td>39.2%</td>
<td>55.3%</td>
<td>11.3%</td>
<td>1.6%</td>
<td>2.4%</td>
<td>43.1%</td>
<td>58.5%</td>
</tr>
</tbody>
</table>
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific information requested and downloaded may relate to the use of our medicine(s) outside of their license.